Sign in
Taking peopleNo phase

Measuring cell stress in hair follicles of adults with hidradenitis suppurativa

Studies skin and blood samples from adults with hidradenitis suppurativa to measure replicative stress.

Key facts

Who runs it
Assistance Publique - Hôpitaux de Paris
Where
France1 site in 1 countryChoose a country to see its sites
Trial code
Registry title
Replicative Stress in Hair Follicle Stem Cells and Pathogeny of Hidradenitis Suppurativa
Status
Recruiting
People taking part
200 people, planned
Started
13 Jun 2022
Expected to end
13 Dec 2029
Type of study
Interventional
Treatments tested
  • Skin biopsy
  • Blood sample
Record updated
6 February 2025

Who can take part

The trial is looking for adults with hidradenitis suppurativa seen at the dermatology clinic of Henri Mondor Hospital. They give a skin biopsy and blood samples.

Age
Over 18 years (record lists 18 Years to 99 Years).
Sex
All sexes can join.
Disease stage
A diagnosis of hidradenitis suppurativa.
Main reasons for not taking part
  • People under legal guardianship (tutorship or curatorship) cannot join.
  • Pregnant or breastfeeding women cannot join.
  • People who refuse to sign the consent form cannot join.
  • People receiving State Medical Aid cannot join.
  • People without a social security system cannot join.
Show the full registry criteria (8)Hide the full registry criteria

Who can take part

  • Patients referred to the consultation of dermatology of Henri Mondor Hospital
  • Diagnosis of Hidradenitis Suppurativa
  • Age> 18 y.o
  • Affiliation to a social security system

Who cannot take part

  • Patient under tutorship or curatorship
  • Breastfeeding or pregnant women
  • Refusal to sign the consent letter
  • Patients benefiting from State Medical Aid

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Hidradenitis suppurativa

This trial is currently available in France.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Hidradenitis Suppurativa is a recurrent chronic inflammatory follicular occlusive disease affecting hair follicles. HS is notoriously difficult and challenging to treat with a high morbidity impact and could be classified as an unmet medical need with no efficient therapeutic options.

Read full original descriptionShow less

Objective:

Investigators previously showed that Outer Root Sheath Cells (ORS) isolated from hair follicle of HS patients (HS-ORS) have a pro-inflammatory phenotype and secrete spontaneously IP-10 and RANTES. To identify the mechanisms involved in the pro-inflammatory phenotype of HS-ORS, investigators performed a transcriptomic analysis in healthy and HS patients. This revealed: (i) an IFN signature, (i) a dysregulation of genes involved in cell proliferation and differentiation, and (iii) an upregulation of DNA damage response and cell cycle G2/M checkpoint pathways in HS-ORS. These findings support the notion that, in HS patients, a perturbation of HF-SC homeostasis leading to an increased proliferation induces a replicative stress and an accumulation of cytoplasmic ssDNA, stimulating IFN synthesis through IFI16-STING pathway. Interestingly, replicative stress in ORS were present in some but not all patients with Hidradenitis Suppurativa. The goal of study is to determine replicative stress in ORS in a large cohort of HS patients.

Method Patients will be enrolled in the Mondor Dermatology department, during routine care. A dermatologist will check all inclusion and exclusion criteria with the technical support of a research technician of the Henri Mondor Clinical Investigation Center. Medical history, clinical data, comorbidities and concomitant therapies will be prospectively recorded in a dedicated case report form. Skin biopsies will be performed in perilesional zone rich in hair follicles. mRNA will be extracted from freshly isolated hair follicle cells and some slides will be prepared and stored at -80°C to perform immunohistochemistry analysis on freshly isolated hair follicle cells. PBMC and serum will be collected.

All these biological samples will allow us to quantify the replicative stress in HS-ORS of each patient, and to quantify several cytokine of interest : IFN de type 1, IL-17, IL-6, TNF-α, IL-10

This study will allow investigators to evaluate the rate of patients with replicative stress in hair follicle stem cells in Hidradenitis Suppurativa. The investigator will also determine whether HF-SC replication stress correlates with clinical characteristics and/or with clinical course and/or comorbidities.

The group in the trial

  • Physiopathologic explorationTreatment being tested

    A non randomised study with one arm, addind experimental acts to standard of care (skin biopsy and biological sample ) in order to explore Hidradenitis Suppurativa physiopathology

    Treatment: Skin biopsy and Blood sample

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Replicative Stress in Hair Follicle Stem Cells and Pathogeny of Hidradenitis Suppurativa
Plain-language title
Measuring cell stress in hair follicles of adults with hidradenitis suppurativaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Criteria questions
Built from NCT05531747, who can take part
Record updated
6 February 2025